Skip to main
ALKS
ALKS logo

Alkermes (ALKS) Stock Forecast & Price Target

Alkermes (ALKS) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 42%
Buy 42%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Alkermes PLC is expected to experience revenue growth through 2030, bolstered by decreasing Invega royalties and the impending patent expiry of Vivitrol, despite some offsetting factors related to the acquisition of Lumryz. The acquisition of Lumryz is projected to enhance Alkermes's financial performance with annualized sales anticipated to reach approximately $265-$275 million by 2025, with further growth expected in subsequent years, positioning the company favorably within the narcolepsy and insomnia markets. Additionally, the encouraging data from alixorexton and ongoing development programs contribute to a robust growth outlook, supported by a strong commercial base that enhances both near- and mid-term financial prospects.

Bears say

Alkermes PLC faces a negative outlook primarily due to anticipated challenges in its key product, Lumryz, including projected sales stagnation and significant patent expirations that threaten future revenue stability. The company also encounters risks from its royalty business erosion and the early-stage nature of its orexin program, which necessitates further validation in larger studies. Additionally, the competitive landscape for orexin receptor agonists is expected to intensify, potentially leading to further market share erosion and impacting long-term growth prospects.

Alkermes (ALKS) has been analyzed by 12 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 42% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alkermes and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alkermes (ALKS) Forecast

Analysts have given Alkermes (ALKS) a Buy based on their latest research and market trends.

According to 12 analysts, Alkermes (ALKS) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alkermes (ALKS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.